New approaches for persistent pulmonary hypertension of newborn

Clinics in Perinatology

Volumn 31, Issue 3, 2004, Pages 591-611

  Konduri, G Ganesh ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE MAGNESIUM; ARGININE; BOSENTAN; CITRULLINE; CYCLIC GMP; FOLIC ACID; ILLICIT DRUG; MAGNESIUM SULFATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E1; SCAVENGER; SILDENAFIL; SUPEROXIDE DISMUTASE; SURFACTANT;

AIR CONDITIONING; BRAIN HEMORRHAGE; CATALYSIS; CLINICAL TRIAL; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART DISEASE; CYANOSIS; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG SAFETY; DUCTUS ARTERIOSUS; ENDOTHELIUM CELL; ENZYME ACTIVITY; FETUS CIRCULATION; HEART ATRIUM SEPTUM DEFECT; HEART OUTPUT; HIGH FREQUENCY OSCILLATION; HUMAN; HYPOTENSION; HYPOXEMIA; INCIDENCE; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MORBIDITY; MORTALITY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; OBSTRUCTION; OXYGENATION; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RETINA DISEASE; RETROLENTAL FIBROPLASIA; REVIEW; RISK ASSESSMENT; SHUNTING; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL; TOBACCO; VASODILATATION;

ADMINISTRATION, INHALATION; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; PROGNOSIS;

EID: 4344620649     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2004.04.001     Document Type: Review

References (109)

1. Fox W.W., Gewitz M.H., Dinwiddie R., Drummond W.H., Peckham G.J. Pulmonary hypertension in the perinatal aspiration syndromes. Pediatrics. 59:1977;205-211
2. Walsh-Sukys M.C., Tyson J.E., Wright L.L., Bauer C.R., Korones S.B., Stevenson D.K., et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 105:2000;14-20
3. Roberts J.D. Jr., Fineman J.R., Morin F.C. III, Shaul P.W., Rimar S., Schreiber M.D., et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med. 336:1997;605-610
4. The Neonatal Inhaled Nitric Oxide Study Group Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 336:1997;597-604
5. Alameh J., Bachiri A., Devisme L., Truffert P., Rakza T., Riou Y., et al. Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur J Pediatr. 161:2002;262-266
6. Bohn D. Congenital diaphragmatic hernia. Am J Respir Crit Care Med. 166:2002;911-915
7. Dawes G.S., Mott J.C., Widdicomb J.G., Wyatt D.G. Changes in the lungs of the newborn lamb. J Physiol (Lond). 121:1953;141-162
8. Cassin S., Dawes G.S., Mott J.C., Ross B.B., Strang L.B. The vascular resistance of the foetal and newly ventilated lung of the lamb. J Physiol (Lond). 171:1964;61-79
9. Velvis H., Moore P., Heymann M.A. Prostaglandin inhibition prevents the fall in pulmonary vascular resistance as a result of rhythmic distension of the lungs in fetal lambs. Pediatr Res. 30:1991;62-68
10. Abman S.H., Chatfield B.A., Hall S.L., McMurtry I.F. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol. 259:1990;H1921-H1927
11. Lakshminrusimha S., Steinhorn R.H. Pulmonary vascular biology during neonatal transition. Clin Perinatol. 26:1999;601-619
12. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526
13. Murad F., Mittal C.K., Arnold W.P., Katsuki S., Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res. 9:1978;145-158
14. Shaul P.W., Farrar M.A., Magness R.R. Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn. Am J Physiol. 265:1993;H1056-H1063
15. Brannon T.S., MacRitchie A.N., Jaramillo M.A., Sherman T.S., Yuhanna I.S., Margraf L.R., et al. Ontogeny of cyclooxygenase-1 and cyclooxygenase-2 gene expression in ovine lung. Am J Physiol. 274:1998;L66-L71
16. Shaul P.W., Wells L.B. Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells. Am J Respir Cell Mol Biol. 11:1994;432-438
17. Shaul P.W., Campbell W.B., Farrar M.A., Magness R.R. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest. 90:1992;2147-2155
18. Konduri G.G., Mattei J. Role of oxidative phosphorylation and ATP release in birth related pulmonary vasodilation in fetal lambs. Am J Physiol Heart Circ Physiol. 283:2002;H1600-H1608
19. Konduri G.G., Mital S., Gervasio C.T., Rotta A.T., Forman K. Purine nucleotides contribute to pulmonary vasodilation caused by birth related stimuli in the ovine fetus. Am J Physiol Heart Circ Physiol. 272:1997;H2377-H2384
20. Konduri G.G., Ou J., Shi Y., Pritchard K.A. Jr. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol. 285:2003;H204-H211
21. Pearson J.D., Slakey L.L., Gordon J.L. Stimulation of prostaglandin production through purinoceptors on cultured porcine endothelial cells. Biochem J. 214:1983;273-276
22. Bloch K.D., Filippov G., Sanchez L.S., Nakane M., de la Monte S.M. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol. 272:1997;L400-L406
23. Hanson K.A., Burns F., Rybalkin S.D., Miller J.W., Beavo J., Clarke W.R. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med. 158:1998;279-288
24. Michel T. Targeting and translocation of endothelial nitric oxide synthase. Braz J Med Biol Res. 32:1999;1361-1366
25. Pritchard K.A., Ackerman A.W., Gross E.R., Stepp D.W., Shi Y., Fontana J.T., et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric oxide synthase. J Biol Chem. 276:2001;17621-17624
26. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 111:2003;1201-1209
27. Song Y., Cardounel A.J., Zweier J.L., Xia Y. Inhibition of superoxide generation from neuronal nitric oxide synthase by heat shock protein 90: implications in NOS regulation. Biochemistry. 41:2002;10616-10622
28. Friebe A., Schultz G., Koesling D. Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO. Biochem J. 335:1998;527-531
29. Liu Y., Terata K., Rusch N.J., Gutterman D.D. High glucose impairs voltage gated K+ channel current in rat small coronary arteries. Circ Res. 89:2001;146-152
30. Landmesser U., Harrison D.G. Oxidative stress and vascular damage in hypertension. Coron Artery Dis. 12:2001;455-461
31. Geggel R.L., Reid L.M. The structural basis of PPHN. Clin Perinatol. 11:1984;525-549
32. Manchester D., Margolis H.S., Sheldon R.E. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol. 126:1976;467-469
33. Perkin R.M., Levin D.L., Clark R. Serum salicylate levels and right to left ductus shunts in newborn infants with persistent pulmonary hypertension. J Pediatr. 96:1980;721-726
34. Abman S.H., Shanley P.F., Accurso F.J. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest. 83:1989;1849-1858
35. Morin F.C. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in newborn lamb. Pediatr Res. 25:1989;245-250
36. Alano M.A., Ngougmna E., Ostrea E.M., Konduri G.G. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 107:2001;519-523
37. Wild L.M., Nickerson P.A., Morin F.C. Ligating the ductus arteriosus before birth remodels the pulmonary vasculature of the lamb. Pediatr Res. 25:1989;251-257
38. Villanueva M.E., Zaher F.M., Svinarich D.M., Konduri G.G. Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res. 44:1998;338-343
39. Pearson D.L., Dawling S., Walsh W., Haoomes J.L., Christman B.W., et al. Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production and carbamoylphosphate synthetase function. N Engl J Med. 344:2001;1832-1838
40. Shaul P.W., Yuhanna I.S., German Z., Chen Z., Steinhorn R.H., Morin F.C. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 272:1997;L1005-L1012
41. Villamor E., Le Cras T.D., Horan M.P., Halbower A.C., Tuder R.M., Abman S.H. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 272:1997;L1013-L1020
42. Black S.M., Johengen M.J., Soifer S.J. Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res. 44:1998;821-830
43. Steinhorn R.H., Russell J.A., Morin F.C. Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 268:1995;H1483-H1489
44. Brennan L.A., Steinhorn R.H., Wedgwood S., Mata-Greenwood E., Roark E.A., Russell J.A., et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ Res. 92:2003;683-691
45. Harker L.C., Kirkpatrick S.E., Friedman W.F., Bloor C.M. Effects of indomethacin on fetal rat lungs: a possible cause of persistent fetal circulation (PFC). Pediatr Res. 15:1981;147-151
46. Frostell C., Fratacci M.D., Wain J.C., Jones R., Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 83:1991;2038-2047. Erratum in: Circulation 1991;84:2212
47. Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 338:1991;1173-1174
48. Roberts J.D., Polaner D.M., Lang P., Zapol W.M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 340:1992;818-819
49. Kinsella J.P., Neish S.R., Shaffer E., Abman S.H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 340:1992;819-820
50. Wessel D.L., Adatia I., Van Marter L.J., Thompson J.E., Kane J.W., Stark A.R., et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 100(5):1997;E7
51. Christou H., Van Marter L.J., Wessel D.L., Allred E.N., Kane J.W., Thompson J.E., et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med. 28(11):2000;3722-3727
52. Clark R.H., Kueser T.J., Walker M.W., Southgate W.M., Huckaby J.L., Perez J.A., et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 342:2000;469-474
53. American Academy of Pediatrics Committee on Fetus and Newborn Use of inhaled nitric oxide. Pediatrics. 106:2000;344-345
54. Kinsella J.P., Truog W.E., Walsh W.F., Goldberg R.N., Bancalari E., Mayock D.E., et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 131:1997;55-62
55. Konduri G.G., Solimano A., Sokol G.M., Singer J., Ehrenkranz R.A., Singhal N., et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 113:2004;559-564
56. Davidson D., Barefield E.S., Kattwinkel J., Dudell G., Damask M., Straube R., et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double masked, placebo controlled, dose-response, multicenter study. Pediatrics. 101:1998;325-334
57. Finer N.N., Etches P.C., Kamstra B., Tierney A.J., Peliowski A., Ryan C.A. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr. 124:1994;302-308
58. Cornfield D.N., Maynard R.C., deRegnier R.A., Guiang S.F. 3rd, Barbato J.E., Milla C.E. Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics. 104:1999;1089-1094
59. Kinsella J.P., Walsh W.F., Bose C.L., Gerstmann D.R., Labella J.J., Sardesai S. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 354:1999;1061-1065
60. Schreiber M.D., Gin-Mestan K., Marks J.D., Huo D., Lee G., Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 349:2003;2099-2107
61. Wung J.T., James L., Kilchevsky E., James E. Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation. Pediatrics. 76:1985;488-494
62. Lotze A., Mitchell B.R., Bulas D.I., Zola E.M., Shalwitz R.A., Gunkel J.H. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr. 132:1998;40-47
63. Cochrane C.G., Revak S.D., Merritt T.A., Schraufstatter I.U., Hoch R.C., Henderson C., et al. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res. 44:1998;705-715
64. Black S.M., Heidersbach R.S., McMullan D.M., Bekker J.M., Johengen M.J., Fineman J.R. Inhaled nitric oxide inhibits nitric oxide synthase activity in lambs: a potential mechanism for rebound pulmonary hypertension. Am J Physiol. 277:1999;H1849-H1856
65. Sokol G.M., Fineberg N.S., Wright L.L., Ehrenkranz R.A. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol. 32:2001;14-19
66. Keller R.L., Hamrick S.E., Kitterman J.A., Fineman J.R., Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Ped Crit Care Med. 5:2004;184-187
67. Atz A.M., Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 91:1999;307-310
68. Neonatal Inhaled Nitric Oxide Study Group (NINOS) Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics. 99:1997;838-845
69. Abman S.H., Kinsella J.P., Schaffer M.S., Wilkening R.B. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics. 92:1993;606-609
70. Subhedar N.V., Shaw N.J. Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide. Arch Dis Child. 77:1997;191-197
71. Shaul P.W., Afshar S., Gibson L.L., Sherman T.S., Kerecman J.D., Grubb P.H., et al. Developmental changes in nitric oxide synthase isoform expression and nitric oxide production in fetal baboon lung. Am J Physiol Lung Cell Mol Physiol. 283:2002;L1192-L1199
72. Afshar S., Gibson L.L., Yuhanna I.S., Sherman T.S., Kerecman J.D., Grubb P.H., et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol. 284:2003;L749-L758
73. Kinsella J.P., Parker T.A., Galan H., Sheridan B.C., Halbower A.C., Abman S.H. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res. 41:1997;457-463
74. Van Meurs K.P., Rhine W.D., Asselin J.M., Durand D.J. Response of premature infants with severe respiratory to inhaled nitric oxide. Pediatr Pulmonol. 24:1997;319-323
75. Kurz S., Harrison D.G. Insulin and the arginine paradox. J Clin Invest. 99:1997;369-370
76. Fineman J.R., Chang R., Soifer S.J. L-Arginine, a precursor of EDRF in vitro, produces pulmonary vasodilation in lambs. Am J Physiol. 261:1991;H1563-H1569
77. Mitani Y., Maruyama K., Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 96:1997;689-697
78. Gorenflo M., Zheng C., Werle E., Fiehn W., Ulmer H.E. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 37:2001;489-492
79. Nagaya N., Uematsu M., Oya H., Sato N., Sakamaki F., Kyotani S., et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 163:2001;887-891
80. Travadi J.N., Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol. 36:2003;529-535
81. Hoeper M.M., Galie N., Simonneau G., Rubin L.J. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 165:2002;1209-1216
82. Stocker C., Penny D.J., Brizard C.P., Cochrane A.D., Soto R., Shekerdemian L.S. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 29:2003;1996-2003
83. Shekerdemian L.S., Ravn H.B., Penny D.J. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res. 55:2004;413-418
84. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 338:1998;1397-1404. Erratum in: N Engl J Med 1998;339:59
85. Marsh C.S., Marden B., Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol. 88:2004;306-307
86. Robbins C.G., Horowitz S., Merritt T.A., Kheiter A., Tierney J., Narula P., et al. Recombinant human superoxide dismutase reduces lung injury caused by inhaled nitric oxide and hyperoxia. Am J Physiol. 272:1997;L903-L907
87. Steinhorn R.H., Albert G., Swartz D.D., Russell J.A., Levine C.R., Davis J.M. Recombinant human superoxide dismutase enhances the effect of inhaled nitric oxide in persistent pulmonary hypertension. Am J Respir Crit Care Med. 164:2001;834-839
88. Kinsella J.P., Parker T.A., Davis J.M., Abman S.H. Recombinant human superoxide dismutase (rhSOD) improves gas exchange in premature lambs with RDS [abstract]. Pediatr Res. 51:2002;472A
89. Oishi P.E., Ovadia B., Myette M., Harmon C., Johengen M., Black S.M., et al. PEG-SOD prevents rebound pulmonary hypertension and the NOS inhibition associated with inhaled nitric oxide therapy in lambs [abstract]. Pediatr Res. 55:2004;59A
90. de Wit C., von Bismarck P., Pohl U. Synergistic action of vasodilators that increase cGMP and cAMP in the hamster cremaster microcirculation. Cardiovasc Res. 28:1994;1513-1518
91. Shimokawa H., Flavahan N.A., Lorenz R.R., Vanhoutte P.M. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br J Pharmacol. 95:1988;1197-1203
92. Hill L.L., Pearl R.G. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol. 86:1999;1160-1164
93. Bos A.P., Tibboel D., Koot V.C., Hazebroek F.W., Molenaar J.C. Persistent pulmonary hypertension in high-risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. J Pediatr Surg. 28:1993;1463-1465
94. Eronen M., Pohjavuori M., Andersson S., Pesonen E., Raivio K.O. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol. 18:1997;3-7
95. Santak B., Schreiber M., Kuen P., Lang D., Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur J Pediatr. 154:1995;233-235
96. Bindl L., Fahnenstich H., Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch Dis Child Fetal Neonatal Ed. 71:1994;F214-F216
97. Kelly L.K., Porta N.F., Goodman D.M., Carroll C.L., Steinhorn R.H. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr. 141:2002;830-832
98. Kato S., Sugimura H., Kishiro I., Machida M., Suzuki H., Kaneko N. Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension. Exp Lung Res. 28:2002;265-273
99. Wasler A., Iberer F., Tscheliessnigg K.H., Metzler H., Gombotz H., Berger J., et al. Preoperative prostaglandin E1 treatment to prevent right ventricular failure after orthotopic heart transplantation. Transpl Int. 5(Suppl 1):1992;S224-S227
100. Tritapepe L., Voci P., Cogliati A.A., Pasotti E., Papalia U., Menichetti A. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med. 27:1999;2180-2183
101. Tamura M., Kurumatani H., Matsushita T. Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. Prostaglandins Leuk Essent Fatty Acids. 64:2001;197-202
102. Konduri G.G., Theodorou A.A., Mukhopadhyay A., Deshmukh D.R. Adenosine triphosphate and adenosine increase the pulmonary blood flow to postanatal levels in fetal lambs. Pediatr Res. 31:1992;451-457
103. Konduri G.G., Woodard L.L. Selective pulmonary vasodilation by low dose infusion of adenosine triphosphate (ATP) in newborn lambs. J Pediatr. 119:1991;94-102
104. Konduri G.G., Woodard L.L., Mukhopadhyay A., Deshmukh D.R. Adenosine is a pulmonary vasodilator in newborn lambs. Am Rev Respir Dis. 146:1992;670-676
105. Konduri G.G., Garcia D.C., Kazzi N.J., Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics. 97:1996;295-300
106. Ng C., Franklin O., Vaidya M., Pierce C., Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med. 5:2004;10-13
107. Brook M.M., Fineman J.R., Bolinger A.M., Wong A.F., Heymann M.A., Soifer S.J. Use of ATP-MgCl2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects. Circulation. 90:1994;1287-1293
108. Daffa S.H., Milaat W.A. Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the neoborn. Saudi Med J. 23:2002;1266-1269
109. Tolsa J.F., Cotting J., Sekarski N., Payot M., Micheli J.L., Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch Dis Child Fetal Neonatal Ed. 72:1995;F184-F187